Though caution is required when the data haven't been published, it could be a landmark in the drug's journey toward FDA ...

Compass Pathways' Phase 3 COMP-360 data met primary endpoints but disappointed vs analyst expectations. See why investors ...

Compass Pathways plc downgraded to Hold after mixed trial results. Explore upcoming catalysts in depression treatment and ...

The DSM still dominates mental health, but it’s time to evolve. Dr. Steven Rondeau reveals how qEEG brain mapping offers a ...

The COMP005 study (NCT05624268) evaluated a placebo against COMP360, a synthetic, proprietary formulation of psilocybin, for ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the successful achievement of the primary endpoint ...

While positive, results from a late-stage clinical trial appear to be raising questions about how useful the company’s ...

Compass Pathways said Monday it achieved its primary endpoint in an early readout from the largest-ever study of psilocybin ...

Compass Pathways’ depression drug trial meets goals but falls short of investor hopes, triggering a sharp share selloff.

Depression. The WHO estimates that depression affects 350 million people worldwide and is one of the leading causes of global disability.3 Population studies in Westernised countries suggest a point ...

A single dose of psilocybin coupled with “talk therapy” can significantly reduce depression in people with cancer for up to ...

Single-dose psilocybin helped reduce depression in half the participants * Lasting effects were// seen even two years after ...